Recently, due to their remarkable specificity for IgA antibodies, IgAPs have been explored as potential treatments for IgAN (Xie et al, 2022; Lamm et al, 2008; Lechner et al, 2016), an autoimmune disease for which no specific therapy is currently available. Here, CD79A is linked to autoimmune disease.